SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
1.900
+0.023 (1.23%)
May 14, 2025, 11:37 AM - Market open
Company Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders.
It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1.
SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
SAB Biotherapeutics, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Samuel Reich |
Contact Details
Address: 777 W 41st St. Miami Beach, Florida 33140 United States | |
| Phone | 605 679 6980 |
| Website | sabbiotherapeutics.com |
Stock Details
| Ticker Symbol | SABS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001833214 |
| CUSIP Number | 78397T103 |
| ISIN Number | US78397T2024 |
| Employer ID | 85-3899721 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Samuel J. Reich | Chief Executive Officer and Executive Chairman |
| Dr. Eddie Joe Sullivan Ph.D. | Co-Founder, President and Director |
| Christine E. Hamilton M.B.A. | Co-Founder and Independent Director |
| Lucy To | Executive Vice President and Chief Financial Officer |
| Dr. Christoph Bausch M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. Alexandra Kropotova M.B.A., M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Edward D. Hamilton D.V.M. | Co-Founder and Board Observer |
| Dr. Carlos N. Carillo Ph.D. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | 10-Q | Quarterly Report |
| Apr 3, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 31, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | 8-K | Current Report |
| Jan 28, 2025 | 8-K | Current Report |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Sep 9, 2024 | 8-K | Current Report |
| Aug 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 8, 2024 | 10-Q | Quarterly Report |